Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
NCT04008121 · View on ClinicalTrials.gov ↗
Study Summary
The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Fluorescein sodium and Zeiss FF450 fundus camera
- COMBINATION_PRODUCT MB-102 and Zeiss FF450 fundus camera
- COMBINATION_PRODUCT Fluorescein sodium and commercially available optical angiography imaging system
- COMBINATION_PRODUCT MB-102 and commercially available optical angiography imaging system
Study Locations (1)
Michigan
- University of Michigan Kellogg Eye Center — Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04008121
The ClinicalTrials.gov registry entry for NCT04008121 describes a study currently listed as recruiting. It is categorized as Early Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediBeacon, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Diabetic Retinopathy appearing as the primary indexed condition, and to 4 interventions — of which Fluorescein sodium and Zeiss FF450 fundus camera is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04008121 reports 1 study location spanning 1 distinct geographic area — top geographies include Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04008121 about?
NCT04008121 is a clinical study titled "Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium". The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.
What is the current status of trial NCT04008121?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2025-11-06. Estimated completion is 2026-12.
What conditions does trial NCT04008121 study?
This clinical trial studies the following conditions: Diabetic Retinopathy, Macular Degeneration, Retinal Vein Occlusion, Retinopathy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04008121?
The interventions under investigation include: Fluorescein sodium and Zeiss FF450 fundus camera (COMBINATION_PRODUCT), MB-102 and Zeiss FF450 fundus camera (COMBINATION_PRODUCT), Fluorescein sodium and commercially available optical angiography imaging system (COMBINATION_PRODUCT), MB-102 and commercially available optical angiography imaging system (COMBINATION_PRODUCT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04008121?
This trial is sponsored by MediBeacon, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04008121 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.